Trial of Essential Amino Acid Supplementation in Protein Deficient Patients Following Total Knee Arthroplasty

Sponsor
Hospital for Special Surgery, New York (Other)
Overall Status
Terminated
CT.gov ID
NCT02926235
Collaborator
(none)
50
1
2
73.4
0.7

Study Details

Study Description

Brief Summary

The goal of this trial is to assess the efficacy of essential amino acids (EAA) on muscle atrophy and malnutrition compared to a placebo in patients following a total knee arthroplasty. The investigators specific objectives included analysis of (1) muscle strength, (2) change in malnutrition, (3) perioperative complications (4) physical activity.

Condition or Disease Intervention/Treatment Phase
  • Drug: Amino Acid
  • Other: Placebo
Phase 4

Detailed Description

Three orthopedic surgeons will participate in the study (MBC, DJM, SAJ). The surgical procedure will be performed as per each surgeon's routine practice. Patients will be asked to ingest 20g of EAA or placebo two times a day between meals 1 week prior and 2 weeks postoperatively. Patients will be given a pill organizer that has two doses per day with either EAA or placebo. Thigh circumference will be measured at baseline, 2 weeks and 6 weeks post-operatively. The mid-thigh measurement will be taken while the patient stands erect with their feet slightly apart and their weight equally distributed. The girth measurement is taken perpendicular to the long axis of the thigh. The tape measure will be placed at the level midway between the trochanterion and tibiale laterale sites each time to ensure that the same location is measured each time. The investigators will measure strength using a handheld dynamometer and performing a straight leg raise and knee extension at 90 degrees on the operative and the non-operative leg preoperatively, 2 weeks and 6 weeks post-operatively. The medial and lateral epicondyles of the femur will be used to position the subject's knee joint through the axis of rotation on the dynamometer. Strength will be tested at 30, 45 and 60 degrees of flexion. Physical activity will be collected using the Knee Society Score at baseline and at 6 weeks postoperatively. After the trial is commenced, there will be no additional enrollment once study numbers have been met.

Study Design

Study Type:
Interventional
Actual Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Randomized Control Trial of Essential Amino Acid Supplementation in Protein Deficient Patients Following Total Knee Arthroplasty
Study Start Date :
Apr 1, 2016
Actual Primary Completion Date :
May 14, 2022
Actual Study Completion Date :
May 14, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Amino Acid

Patients will be asked to ingest 20g of EAA o two times a day between meals 1 week prior and 2 weeks postoperatively.

Drug: Amino Acid
Treatment arm

Placebo Comparator: Placebo

Patients will be asked to ingest 20g of placebo two times a day between meals 1 week prior and 2 weeks postoperatively.

Other: Placebo

Outcome Measures

Primary Outcome Measures

  1. Change Quad Strength [Change between preop and 6 weeks.]

    As Measured by Quad circumference in inches

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • All patients will be undergoing a primary unilateral total knee arthroplasty for a diagnosis of osteoarthritis
Exclusion Criteria:
  • All patients who were wheelchair bound preoperatively

  • All patients who cannot participate in an outpatient physical therapy program for 3 days per week after surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital for Special Surgery New York New York United States 10021

Sponsors and Collaborators

  • Hospital for Special Surgery, New York

Investigators

  • Principal Investigator: David Mayman, MD, Hospital for Special Surgery, New York

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospital for Special Surgery, New York
ClinicalTrials.gov Identifier:
NCT02926235
Other Study ID Numbers:
  • 2015-067
First Posted:
Oct 6, 2016
Last Update Posted:
Aug 8, 2022
Last Verified:
Aug 1, 2022
Keywords provided by Hospital for Special Surgery, New York
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 8, 2022